![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Leukemia |
Free Subscription
1 Acta Haematol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Leukemia is free of charge.
Acquired Factor V Deficiency: A New Cause of Bleeding in Patients with Chronic
Myeloid Leukemia and Extreme Leukocytosis?
Acta Haematol. 2022 May 2. pii: 000524630. doi: 10.1159/000524630.
PubMed
Abstract available
A Novel Adoptive Synthetic TCR and Antigen Receptor (STAR) T-Cell Therapy for
B-Cell Acute Lymphoblastic Leukemia.
Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26586.
PubMed
Abstract available
A phase 1b study of glasdegib + azacitidine in patients with untreated acute
myeloid leukemia and higher-risk myelodysplastic syndromes.
Ann Hematol. 2022 Apr 30. pii: 10.1007/s00277-022-04853.
PubMed
Abstract available
How I treat high-risk acute myeloid leukemia using pre-emptive adoptive cellular
immunotherapy.
Blood. 2022 May 5. pii: 485176. doi: 10.1182/blood.2021012411.
PubMed
Abstract available
Tomizawa D, Miyamura T, Imamura T, et al. A risk-stratified therapy for infants
with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood.
2020;136(16):1813-1823.
Blood. 2022;139:2848.
PubMed
Approval of brexucabtagene autoleucel for adults with relapsed and refractory
acute lymphocytic leukemia.
Blood. 2022 May 4. pii: 485154. doi: 10.1182/blood.2021014892.
PubMed
Abstract available
Anti-CCR9 Chimeric Antigen Receptor T cells for T Cell Acute Lymphoblastic
Leukemia.
Blood. 2022 May 4. pii: 485152. doi: 10.1182/blood.2021013648.
PubMed
Abstract available
New hope to prevent ALL relapse after transplant.
Blood. 2022;139:2580-2581.
PubMed
Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study
to evaluate the improvement in disease-free survival by adding very low dose
6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in
pediatric and ad
BMC Cancer. 2022;22:483.
PubMed
Abstract available
Circulating lnc-LOC as a novel noninvasive biomarker in the treatment
surveillance of acute promyelocytic leukaemia.
BMC Cancer. 2022;22:481.
PubMed
Abstract available
Dynamic trajectory of platelet counts after the first cycle of induction
chemotherapy in AML patients.
BMC Cancer. 2022;22:477.
PubMed
Abstract available
Impact of conditioning regimen intensity on outcomes of second allogeneic
hematopoietic cell transplantation for secondary acute myelogenous leukemia.
Bone Marrow Transplant. 2022 Apr 30. pii: 10.1038/s41409-022-01693.
PubMed
Abstract available
CAR T cells are in it [CD]4 the long haul.
Cell. 2022;185:1112-1114.
PubMed
Abstract available
A high prevalence of myeloid malignancies in progeria with Werner syndrome is
associated with p53 insufficiency.
Exp Hematol. 2022;109:11-17.
PubMed
Abstract available
EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
Exp Hematol. 2022;107:1-8.
PubMed
Abstract available
A Novel HNRNPH1::ERG Rearrangement in Aggressive Acute Myeloid Leukemia.
Genes Chromosomes Cancer. 2022 May 3. doi: 10.1002/gcc.23051.
PubMed
Abstract available
Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny
Labeling.
J Clin Oncol. 2022;40:1102-1110.
PubMed
Abstract available
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior
Outcomes After CD19-CAR for B-ALL.
J Clin Oncol. 2022;40:932-944.
PubMed
Abstract available
Responsible enzymes for metabolizing vitamin D in patients with acute leukemia
and the relationship with treatment outcomes: a case-control study.
Leuk Lymphoma. 2022 May 4:1-7. doi: 10.1080/10428194.2022.2056174.
PubMed
Abstract available
A phase 1b study of atezolizumab in combination with guadecitabine for the
treatment of acute myeloid leukemia.
Leuk Lymphoma. 2022 May 1:1-9. doi: 10.1080/10428194.2022.2057484.
PubMed
Abstract available
Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced
treatment with imatinib: a 20-year single-centre experience.
Leuk Lymphoma. 2022 May 2:1-11. doi: 10.1080/10428194.2022.2068000.
PubMed
Abstract available
Multiple cells of origin in common with various types of mouse N-Myc acute
leukemia.
Leuk Res. 2022;117:106843.
PubMed
Abstract available
MLL1 inhibition reduces IgM levels in Waldenstrom macroglobulinemia.
Leuk Res. 2022;116:106841.
PubMed
Abstract available
Population-based targeted RNA sequencing reveals novel disease-related gene
fusions in pediatric and adult T-ALL.
Leuk Res. 2022;116:106825.
PubMed
Abstract available
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic
phase chronic myeloid leukaemia.
Leukemia. 2022;36:1227-1236.
PubMed
Abstract available
Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid
dendritic cell neoplasm and frequently sharing a clonal origin in elderly
patients.
Leukemia. 2022;36:1343-1350.
PubMed
Abstract available
In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant
to targeted inhibitors of mutant IDH1/2.
Leukemia. 2022;36:1313-1323.
PubMed
Abstract available
Multi-omics reveals mitochondrial metabolism proteins susceptible for drug
discovery in AML.
Leukemia. 2022;36:1296-1305.
PubMed
Abstract available
Associations of history of vaccination and hospitalization due to infection with
risk of monoclonal B-cell lymphocytosis.
Leukemia. 2022;36:1404-1407.
PubMed
IPO11 regulates the nuclear import of BZW1/2 and is necessary for AML cells and
stem cells.
Leukemia. 2022;36:1283-1295.
PubMed
Abstract available
Bendamustine: A review of pharmacology, clinical use and immunological effects
(Review).
Oncol Rep. 2022;47.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by